Tom Norton

We are now less than three weeks away from the initial sign up period for Obamacare. After October 1st, the reality of the program and all that it portends for the future of the US pharmaceutical industry will begin to make itself apparent

As many of you may recall, earlier this year I commented on a section of the new Obamacare law that directed Members of Congress and their staffs to participate in the new healthcare program, effective January 1, 2014.

If you are an Rx regional sales director or a product marketing manager, I have a somewhat provocative question for you: How exactly are you planning your 2014 Medicaid strategy?

As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program.

This past week or so, with Obamacare’s start up less than a year away, we have been treated to several entertaining vignettes as the nation’s governors begin to wrestle with the realities of the new healthcare law.

Of the many issues involved with the actual implementation of the 2010 Affordable Care Act, aka, “Obamacare”, few are more intriguing to me than those that personally impact Members of Congress (MOCs).

With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun. Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th

If you’re like me, you probably bounded out of bed on Thursday morning, took in all the news you could find about the Supreme Court and healthcare reform…and then you waited.

After almost nine years of working at Pharm Exec magazine, it’s time for me to move on.

The Supreme Court will open up deliberations on the constitutionality of three important parts of healthcare reform (HCR) this month